Want to see AU:EZZ full AI Analyst Report?
Top Page
EZZ Life Science Holdings Ltd.
(Sydney:EZZ)
Select Model
Select Model
Rating:52Neutral
Price Target:
AU$0.51
▼(-21.09% Downside)
Action:Reiterated
Date:09/06/26
The score is driven primarily by financial performance: despite a low-debt balance sheet, FY2026 deterioration (losses and negative operating/free cash flow) weighs heavily. Technicals remain weak versus longer-term moving averages, while valuation is supported by the high dividend yield but offset by a negative P/E due to losses.
Positive Factors
Low leverage
Very low leverage limits debt-related financial risk and preserves flexibility during operational volatility. A sizable equity base can support continued investment, absorb weaker trading conditions, and give management more options while profitability is being rebuilt.
Negative Factors
Revenue contraction
The sharp revenue decline signals weaker demand, distribution, or commercial execution and reduces operating leverage across the business. Unless growth stabilizes, a smaller revenue base can make marketing and fixed operating costs harder to absorb over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Very low leverage limits debt-related financial risk and preserves flexibility during operational volatility. A sizable equity base can support continued investment, absorb weaker trading conditions, and give management more options while profitability is being rebuilt.
Read all positive factors
EZZ Life Science Holdings Ltd. (EZZ) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$23.52M
Dividend Yield8.03%
Average Volume (3M)14.76K
Price to Earnings (P/E)―
Beta (1Y)1.05
Revenue Growth-30.79%
EPS Growth-177.68%
CountryAU
Employees11
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.11
Shares Outstanding47,043,200
10 Day Avg. Volume25,496
30 Day Avg. Volume14,756
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.70
Price to Sales (P/S)0.37
P/FCF Ratio-1.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.24
Revenue Forecast (FY)AU$105.10M
EZZ Life Science Holdings Ltd. Business Overview & Revenue Model
Company Description
EZZ Life Science Holdings Limited, an Australian company, specializes in offering a range of skincare and consumer health products, with its market presence extending across Australia, New Zealand, Mainland China, and other international territori...
How the Company Makes Money
EZZ primarily makes money by selling its branded health and wellness products (e.g., supplements/nutraceutical-type consumer health products) to customers and channel partners. Revenue is generated through: (1) Direct-to-consumer sales via online/...
EZZ Life Science Holdings Ltd. Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
78
Positive
Cash Flow
34
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 46.28M | 66.87M | 66.44M | 37.14M | 15.02M |
| Gross Profit | 25.77M | 49.72M | 50.95M | 27.20M | 7.51M |
| EBITDA | 43.88M | 11.10M | 10.38M | 5.09M | 1.90M |
| Net Income | -5.32M | 6.73M | 6.96M | 3.63M | 1.31M |
Balance Sheet | |||||
| Total Assets | 27.64M | 33.96M | 25.55M | 17.64M | 14.27M |
| Cash, Cash Equivalents and Short-Term Investments | 9.72M | 20.85M | 19.02M | 13.83M | 10.46M |
| Total Debt | 478.59K | 304.49K | 123.86K | 478.59K | 104.57K |
| Total Liabilities | 3.15M | 5.87M | 4.23M | 3.06M | 2.88M |
| Stockholders Equity | 24.49M | 28.09M | 21.32M | 14.58M | 11.39M |
Cash Flow | |||||
| Free Cash Flow | -8.79M | 4.09M | 5.73M | 3.91M | 1.89M |
| Operating Cash Flow | -8.76M | 4.35M | 6.14M | 4.01M | 1.90M |
| Investing Cash Flow | -652.32K | -546.93K | -441.17K | -101.78K | -13.18K |
| Financing Cash Flow | -1.26M | -2.17M | -582.45K | -761.72K | -277.36K |
EZZ Life Science Holdings Ltd. Technical Analysis
Negative
0.64
Price Trends
0.48
Positive
0.54
Negative
1.00
Negative
Market Momentum
0.01
Positive
48.52
Neutral
14.27
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EZZ, the sentiment is Negative. The current price of 0.64 is above the 20-day moving average (MA) of 0.51, above the 50-day MA of 0.48, and below the 200-day MA of 1.00, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 48.52 is Neutral, neither overbought nor oversold. The STOCH value of 14.27 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:EZZ.
EZZ Life Science Holdings Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | AU$80.94M | 22.05 | 46.74% | ― | 29.68% | 1520.00% | |
52 Neutral | AU$23.52M | -4.42 | -20.36% | 8.03% | -30.79% | -177.68% | |
52 Neutral | AU$5.95M | -1.56 | 80.84% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$57.47M | -0.65 | -118.74% | ― | 499.47% | 31.20% | |
44 Neutral | AU$3.16M | -2.94 | -101.34% | ― | ― | 64.58% | |
43 Neutral | AU$12.91M | -3.10 | -31.88% | ― | 5.85% | 42.92% |
* Healthcare Sector Average
AU:EZZ
EZZ Life Science Holdings Ltd.
0.50
-1.66
-76.86%
AU:ZLD
Zelira Therapeutics
0.50
0.13
33.33%
AU:IMC
Immuron Limited
0.04
-0.03
-42.86%
AU:ANR
Anatara Lifesciences Ltd
0.01
0.00
0.00%
AU:BOT
Botanix Pharmaceuticals Limited
0.02
-0.12
-85.00%
AU:BIO
Biome Australia Ltd
0.36
-0.13
-26.80%
EZZ Life Science Holdings Ltd. Corporate Events
EZZ Life Science Outlines 2026 Corporate Governance and Diversity Framework
Sep 1, 2026
EZZ Life Science Holdings has released its corporate governance statement for the year ended 30 June 2026, confirming broad adherence to the ASX Corporate Governance Council’s 4th edition principles and recommendations. The board has formali...
EZZ Life Science Releases Annual Report for Year Ended 30 June 2026
Aug 31, 2026
EZZ Life Science Holdings Ltd. has released its annual report for the year ended 30 June 2026, providing shareholders and stakeholders with a formal update on its financial and operational performance. The publication of the 2026 annual report mar...
EZZ Life Science Swings to Loss as Revenue Slides and Credit Provisions Rise
Aug 31, 2026
EZZ Life Science Holdings Limited reported a steep downturn for the year ended 30 June 2026, with revenues from ordinary activities falling 36.39% to $46.3 million and a swing from a prior-year profit to a net loss after tax of $5.3 million. Under...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.